US sales momentum, upward revision in margin guidance to support Cipla

The company's market share in Lanreotide (growth hormone disorder drug) improved from 18 per cent in Q1FY24 to 20 per cent now

A strong performance in the September quarter, upward revision in margin guidance and sustained momentum in US sales helped the stock of pharmaceutical major Cipla to gain 1.6 per cent in trade on Monday. Brokerages have upgraded the earnings estimates for FY24  by 6-9 per cent to factor in the improved margin guidance and sales in the US market. 

Led by the US market, which rose by 31 per cent, the company posted a 16 per cent growth in revenues. The US market accounted for 28 per cent of sales. US revenues at $229 million were its highest ever in